Net Cash Provided by (Used in) Financing Activities in USD of Anika Therapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Anika Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Anika Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$5.44M, a 139% decline year-over-year.
  • Anika Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$12.7M, a 101% decline from 2023.
  • Anika Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$6.32M, a 30.3% decline from 2022.
  • Anika Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$4.85M, a 28.4% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Anika Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$5.44M -$3.17M -139% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q1 2024 -$2.27M -$660K -40.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q1 2023 -$1.61M -$751K -87.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 -$862K -$411K -91.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q1 2021 -$451K -$310K -220% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 -$141K -$22K -18.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 -$119K +$1.1M +90.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-22
Q1 2018 -$1.22M -$1.26M -3083% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q1 2017 $41K +$24.4M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q1 2016 -$24.3M -$26.2M -1382% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q1 2015 $1.9M -$3.61M -65.5% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-03
Q1 2014 $5.5M +$4.74M +623% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-04
Q1 2013 $762K +$653K +600% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-05
Q1 2012 $109K +$480K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-06
Q1 2011 -$371K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-07

Anika Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$12.7M -$6.41M -101% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-17
2023 -$6.32M -$1.47M -30.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-17
2022 -$4.85M +$1.93M +28.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-17
2021 -$6.78M -$3.01M -79.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-15
2020 -$3.77M +$4.37M +53.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-16
2019 -$8.14M +$20.8M +71.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-11
2018 -$28.9M -$29.2M -9305% Jan 1, 2018 Dec 31, 2018 10-K/A 2021-04-26
2017 $314K +$24.3M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-06
2016 -$24M -$25.1M -2334% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 $1.07M -$4.26M -79.9% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-27
2014 $5.33M +$11M Jan 1, 2014 Dec 31, 2014 10-K 2017-02-24
2013 -$5.69M -$4.93M -650% Jan 1, 2013 Dec 31, 2013 10-K 2016-03-10
2012 -$759K +$406K +34.9% Jan 1, 2012 Dec 31, 2012 10-K 2014-03-13
2011 -$1.17M +$172K +12.9% Jan 1, 2011 Dec 31, 2011 10-K 2014-03-13
2010 -$1.34M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.